Magnesium Supplementation May Not Be Protective against Carboplatin-Induced Nephrotoxicity But May Be Beneficial for Children Suffering Malignancies: A Randomized Clinical Trial
Alizadeh Hadadhania M, Ghaffari K, Absalan A, Eghbali A, Rahimi Afzal R, Ghasemi A, Eghbali A
Advanced biomedical research · 3 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Arak University of Medical Sciences
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2023-01-01 · Adv Biomed Res · vol. 12 · issue 1 · p. 11
- Publisher
- Medknow
- Cited
- 3 citations · more than 61% of similar papers · 0.5× the field average
- References
- 36 works
- Access
- Open access (journal) · CC-BY-NC-ND
- Research areas
- Chemotherapy-induced organ toxicity mitigation · Magnesium in Health and Disease · Biomedical Research and Pathophysiology
- Keywords
- Medicine, Carboplatin, Creatinine, Blood urea nitrogen, Renal function, Placebo, Nephrotoxicity, Urology, Randomized controlled trial, Magnesium, Clinical trial, Internal medicine, Chemotherapy, Gastroenterology, Kidney, Cisplatin, Pathology
9 authors
From IR
- Marzie Alizadeh HadadhaniaArak University of Medical Sciences
- Kazem GhaffariImam Khomeini Hospital
- Abdorrahim AbsalanImam Khomeini Hospital
- Aygin Eghbali · correspondingIran University of Medical Sciences
- Aygin EghbaliArak University of Medical Sciences; Iran University of Medical Sciences
- Roghayeh Rahimi AfzalArak University of Medical Sciences; Semnan University of Medical Sciences
Abstract
Background
Magnesium oxide may be effective in renal insufficiency prevention after carboplatin therapy. We have evaluated magnesium oxide impression on the serum creatinine (Cr) and blood urea nitrogen (BUN) levels plus glomerular filtration rate (GFR) in cancerous children.
Materials and methods
A group of children with different cancers (n = 18) was treated with 250 mg/day magnesium oxide supplementation (MOS) and compared with a matched placebo-treated group (n = 18). After 2 weeks, carboplatin chemotherapy started. We compared serum Cr, BUN, and GFR values before and 3 and 7 days post intervention.
Results
Serum Cr and BUN were increased significantly 3 and 7 days after intervention in both the groups. Serum Cr and BUN were not statistically different between the MOS and placebo groups before the intervention and 3 or 7 days after carboplatin administration (P > 0.05). Three days after the intervention, the GFR reduced from 101.38 ± 14.67 to 90.11 ± 10.52 mL/min/1.73 m2 in the MOS group. Furthermore, in the placebo group, 3 days after the intervention, the GFR was reduced from 97.5 ± 9.71 to 92.33 ± 10.61 mL/min/1.73 m2. Further, in the MOS group, after 7 days of the intervention, the GFR was reduced to 84.11 ± 12.47 mL/min/1.73 m2. In the placebo group, after 7 days of the intervention, the GFR was diminished to 85.38 ± 10.66 mL/min/1.73 m2 (P = 0.371).
Conclusion
The current study suggests that magnesium supplementation does not prevent carboplatin-induced nephrotoxicity in children with malignancies. Anyway, we propose magnesium oxide supplementation for this group of pediatrics because magnesium is an essential element for cell and tissue growth, maintenance, and metabolism.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-SA).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.